With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
Oct. 24, 2019: A computerized antiretroviral recommendation tool; higher Fiebig stage equals more frequent viral load blips; low prescription refill rates among Americans starting treatment; internalized stigma and HIV outcomes.
Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.